Medicare Enrolled
Dr. John Peterson, MD
Medical Oncology · St Petersburg, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Peterson from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Peterson? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Peterson
Dr. John Peterson is a medical oncology in St Petersburg, FL, with 20 years in practice. Based on federal Medicare data, Dr. Peterson performed 138,980 Medicare services across 3,451 unique beneficiaries.
Between the years covered by Open Payments, Dr. Peterson received a total of $13,334 from 88 pharmaceutical and/or device companies across 654 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Peterson is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 19% volume in FL$ $13,334 industry payments
Medicare Practice Summary
Medicare Utilization ↗138,980
Medicare services
Top 19% in FL for medical oncology
3,451
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,949 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 44,880 | $0 | $4 |
| Filgrastim injection (Zarxio) for white blood cells | 25,560 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 17,800 | $43 | $137 |
| Iron sucrose injection (Venofer) | 13,100 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 9,780 | $18 | $51 |
| Epoetin alfa injection (Procrit) for anemia | 9,450 | $6 | $23 |
| Anti-nausea injection (aprepitant) | 6,500 | $1 | $5 |
| Complete blood count (CBC) with differential | 1,845 | $8 | $29 |
| Dexamethasone injection (steroid) | 1,722 | $0 | $3 |
| Blood draw (venipuncture) | 1,700 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,010 | $1 | $28 |
| Drug injection, under skin or into muscle | 877 | $10 | $69 |
| Office visit, established patient (30-39 min) | 553 | $94 | $339 |
| Office visit, established patient (20-29 min) | 539 | $63 | $239 |
| Anti-nausea injection (ondansetron/Zofran) | 516 | $0 | $9 |
| Administration of chemotherapy into vein, 1 hour or less | 349 | $97 | $378 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 296 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 285 | $47 | $189 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 275 | $22 | $84 |
| Injection of additional new drug or substance into vein | 251 | $12 | $61 |
| Office visit, established patient, complex (40-54 min) | 185 | $132 | $474 |
| Injection, magnesium sulfate, per 500 mg | 166 | $1 | $2 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 161 | $15 | $56 |
| Injection, diphenhydramine hcl, up to 50 mg | 101 | $1 | $3 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 96 | $133 | $562 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 89 | $3 | $11 |
| Administration of chemotherapy into vein, each additional hour | 87 | $22 | $79 |
| Infusion into a vein for hydration, each additional hour | 78 | $9 | $42 |
| Administration of additional new drug or substance into vein, 1 hour or less | 74 | $48 | $178 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 73 | $17 | $59 |
| Red blood count, automated test | 71 | $4 | $10 |
| New patient office visit, complex (60-74 min) | 60 | $160 | $585 |
| Initial hospital admission, high complexity | 57 | $132 | $556 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 55 | $23 | $89 |
| Injection of drug or substance into vein | 46 | $27 | $156 |
| Hospital follow-up visit, moderate complexity | 44 | $61 | $197 |
| Automated urinalysis | 42 | $2 | $8 |
| Infusion, normal saline solution , 1000 cc | 40 | $2 | $7 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 38 | $126 | $637 |
| Administration of additional new drug or substance into vein using push technique | 35 | $42 | $170 |
| Hospital follow-up visit, high complexity | 28 | $84 | $285 |
| Infusion into a vein for hydration, 31-60 minutes | 24 | $25 | $156 |
| New patient office visit (45-59 min) | 22 | $127 | $453 |
| Drawing of blood for a medical problem | 20 | $50 | $277 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
32.9% high complexity
63.1% medium
3.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,334
Total received (2018-2024)
Avg $1,905/year across 7 years
Top 38% in FL for medical oncology
88
Companies
654
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,209 (99.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$125 (0.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,328
2023$2,707
2022$1,462
2021$132
2020$415
2019$2,701
2018$2,589
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,255
AstraZeneca Pharmaceuticals LP
$898
Janssen Biotech, Inc.
$703
E.R. Squibb & Sons, L.L.C.
$698
PFIZER INC.
$678
Lilly USA, LLC
$578
Incyte Corporation
$429
Amgen Inc.
$413
Celgene Corporation
$406
Daiichi Sankyo Inc.
$398
Genentech USA, Inc.
$346
Takeda Pharmaceuticals U.S.A., Inc.
$291
Merck Sharp & Dohme LLC
$286
JAZZ PHARMACEUTICALS INC.
$271
Gilead Sciences, Inc.
$259
GENZYME CORPORATION
$238
Merck Sharp & Dohme Corporation
$234
Novocure Inc.
$225
Astellas Pharma US Inc
$215
GlaxoSmithKline, LLC.
$211
Exelixis Inc.
$159
Kyowa Kirin, Inc.
$154
Allergan Inc.
$154
Kite Pharma, Inc.
$150
EMD Serono, Inc.
$144
Bayer HealthCare Pharmaceuticals Inc.
$144
TerSera Therapeutics LLC
$144
SOBI, INC
$143
Axonics, Inc.
$137
EISAI INC.
$134
CSL Behring
$131
Seagen Inc.
$130
TESARO, Inc.
$125
Dendreon Pharmaceuticals LLC
$124
Eisai Inc.
$120
Seattle Genetics, Inc.
$117
PharmaEssentia USA Corporation
$112
Pharmacosmos Therapeutics Inc.
$109
Puma Biotechnology, Inc.
$90
ABBVIE INC.
$89
Janssen Pharmaceuticals, Inc
$86
TAIHO ONCOLOGY, INC.
$82
Stemline Therapeutics Inc.
$82
Boehringer Ingelheim Pharmaceuticals, Inc.
$75
Fennec Pharmaceuticals, Inc.
$73
BeiGene USA, Inc.
$71
Spectrum Pharmaceuticals Inc.
$70
Pharmacyclics LLC, An AbbVie Company
$65
Ipsen Biopharmaceuticals, Inc
$64
AbbVie, Inc.
$60
Regeneron Healthcare Solutions, Inc.
$57
ARRAY BIOPHARMA INC
$56
Clovis Oncology, Inc.
$55
G1 Therapeutics, Inc.
$54
AMAG Pharmaceuticals, Inc.
$47
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$46
Acrotech Biopharma Inc.
$44
Novo Nordisk Inc
$42
Sumitomo Pharma America, Inc.
$39
Alexion Pharmaceuticals, Inc.
$28
SpringWorks Therapeutics, Inc.
$24
Allergan, Inc.
$24
SERVIER PHARMACEUTICALS LLC
$24
Pharmacyclics LLC, an AbbVie Company
$24
Rigel Pharmaceuticals, Inc.
$23
Blueprint Medicines Corporation
$21
Genmab U.S., Inc.
$20
Aurobindo Pharma USA, Inc.
$20
Shire North American Group Inc
$20
PUMA BIOTECHNOLOGY, INC.
$20
AbbVie Inc.
$20
Array BioPharma Inc.
$18
Sobi, Inc
$18
Global Blood Therapeutics, Inc.
$18
GE HealthCare
$17
Organon LLC
$17
SHIELD THERAPEUTICS INC
$17
Progenics Pharmaceuticals, Inc.
$16
Helsinn Therapeutics (U.S.), Inc.
$15
MEDIVATION FIELD SOLUTIONS LLC
$15
Coherus Biosciences Inc.
$14
NOVARTIS PHARMACEUTICALS CORPORATION
$14
Alnylam Pharmaceuticals Inc.
$14
Agios Pharmaceuticals, Inc.
$14
Epizyme, Inc.,
$13
Collegium Pharmaceutical, Inc.
$12
Dova Pharmaceuticals
$12
Lexicon Pharmaceuticals, Inc.
$10
Top 3 companies account for 21.4% of total payments
Associated products mentioned in payments ›
ACCRUFER · ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AUGTYRO · AVYCAZ · AYVAKIT · Abraxane · Afstyla · Alecensa · Aliqopa · Avastin · Axonics · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Beleodaq · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · COSELA · CYRAMZA · Cabometyx · DALVANCE · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMEND · ENHERTU · ENJAYMO · ERLEADA · Enhertu · Epkinly · Erleada · FARESTON · FERAHEME · FRUZAQLA · Folotyn · GAMMAGARD · GAUCHER-DISEASE · GAZYVA · GILOTRIF · GIVLAARI · HEMGENIX · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Idelvion · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · OGSIVEO · OJJAARA · ONTRUZANT · OPDIVO · ORGOVYX · OXBRYTA · Oncology · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · PYLARIFY · Padcev · Pedmark · Perjeta · Pomalyst · Quzyttir · REBLOZYL · Rebinyn · Revlimid · Rubraca · SANDOSTATIN LAR · SARCLISA · SOLIRIS · SOMATULINE DEPOT · SUTENT · Somatuline Depot · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEFLARO · TEVIMBRA · TIBSOVO · TUKYSA · Tavalisse · Tibsovo · Trodelvy · UCERIS · UCERIS TABLETS · ULTOMIRIS · Udenyca · VARUBI · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · Venclexta · Vitrakvi · XARELTO · XTANDI · Xermelo · Xofigo · Xospata · Xtampza ER · Xtandi · Yescarta · ZEJULA · ZENPEP · ZEPZELCA · ZOLADEX · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $10 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
65
Per 100K population
6.8
County median income
$70,293
Nearest hospital
ORLANDO HEALTH BAYFRONT HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Peterson is a mixed practice specialist, with above-average Medicare volume (top 19% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Peterson experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Peterson performed 44,880 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Peterson receive payments from pharmaceutical companies?
Yes. Dr. Peterson received a total of $13,334 from 88 companies across 654 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Peterson's costs compare to other medical oncologys in St Petersburg?
Dr. Peterson's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Peterson) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in St Petersburg
Browse medical oncologys in St Petersburg ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology